Opinion

Video

Eculizumab Impact on PNH Treatment Landscape and Unmet Needs in PNH Management

Medical experts highlight unmet needs in the PNH treatment landscape and considerations for utilizing eculizumab.

Video content above is prompted by the following:

  • Eculizumab was the first-in-class complement C5 inhibitor for PNH. Can you elaborate on the mechanism of action of eculizumab and its impact on the management of PNH?
  • Please elaborate on the persistent unmet needs in PNH management, such as residual intravascular hemolysis and C3-mediated extravascular hemolysis. How do they contribute to the treatment burden for patients?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr Carrie Kitko
Dr Ibrahim Aldoss
1 expert is featured in this series.
Miriam Freimer, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo